Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−68.4334 USD
−15.04 M USD
0.00 USD
1.70 M
About Revelation Biosciences, Inc.
Sector
Industry
CEO
James M. Rolke
Website
Headquarters
San Diego
Founded
2019
ISIN
US76135L1199
FIGI
BBG00Y646SC9
Revelation Biosciences, Inc. is a clinical-stage life sciences company, which focuses on the development of immunologic-based therapies for the prevention and treatment of disease. Its product candidates include REVTx-99b, its lead therapeutic candidate being developed for allergic rhinitis and chronic nasal congestion, REVDx 501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation, and REVTx 200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. The company was founded on November 20, 2019 and is headquartered in San Diego, CA.
Displays a symbol's price movements over previous years to identify recurring trends.